Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke

Clinical Hemorheology and Microcirculation

Volumn 30, Issue 3-4, 2004, Pages 237-242

  Pongrácz, Endre ^a  

^a MI Central Hospital   (Hungary)

Author keywords

Aggregation; Aspirin resistance; Clopidogrel; Ischemic stroke; Platelet; Secondary prevention; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; TICLOPIDINE;

ADRENALIN RELEASE; ADULT; ANTICOAGULANT THERAPY; BLOOD SAMPLING; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; COLLAGEN METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOSIS PREVENTION; TREATMENT INDICATION;

ADENOSINE DIPHOSPHATE; ADULT; ASPIRIN; BRAIN ISCHEMIA; COHORT STUDIES; COLLAGEN; EPINEPHRINE; FEMALE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; TICLOPIDINE;

EID: 3242666880     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. A.M. Ehrly, Therapeutische Hamorheologie, Berlin, Springer-Verlag, 1989, p. 21.
2. C.P. Warlow, M.S. Dennis, J. van Gijn, G.J. Hankey, P.A.G. Sandercock, J.M. Bamford and J.M. Wardlaw, Stroke: A Practical Guide to Management, Blackwell Science, Oxford, UK, 2001.
3. European Stroke Initiative (EUSI) Recommendations for stroke management, Cerebrovasc. Dis. 10 (suppl. 3) (2000), 16-17.
4. M. Busch, F. Masuhr and K.M. Einhaupl, Medical and surgical prevention of stroke: experiences around the world, Cerebrovasc. Dis. 1 (suppl.) (1997), 22-28.
5. T.E. Welty, Cerebrovascular disorders, in: L.E. Koda Young and M.A. Kimble, eds, Applied Therapeutics: The Clinical Use of Drugs, Applied Therapeutics Inc, Vancouver, 1995.
6. A Swedish Cooperative Study, High-dose acetylsalicylic acid after cerebral infarction, Stroke 18 (1987), 325-334.
7. Antiplatelet Trialists' Collaboration, Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, BMJ 308 (1994), 81-106.
8. G.V.R. Born, Aggregation of blood platelets by adenosine diphosphate and reversal, Nature 194 (1962), 927.
9. C. Patrono and G. Roth, Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen?, Stroke 27 (1998), 756-760.
10. ESPS Group, European Stroke Prevention Study (ESPS): principal end-points, Lancet ii (1987), 1351-1354.
11. ESPS Group, European Stroke Prevention Study, Stroke 21 (1990), 1123-1130.
12. A. Algra van J. Gijn, Cumulative meta-analyses of aspirin efficacy after cerebral ischaemia of arterial origin, J. Neurol. Neurosurg. Psychiatry 66 (1999), 255.
13. C.M. Helgason, K.L. Tortorice, S.R. Winkler et al., Aspirin response and failure in cerebral infarction, Stroke 24 (1993), 345-350.
14. J.W. Eikelboom, J. Hirsh, I. Weitz, M. Johnston, Q. Yi and S. Yusuf, Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation 105 (2002), 1650-1655.
15. J.A. Cambria-Kiely and P.J. Gandhi, Aspirin resistance and genetic polymorphisms, J. Thromb. Thrombolysis 14(1) (2002), 51-58.
16. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White and E.J. Topol, A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease, J. Am. Coll. Cardiol. 41(6) (2003), 966-968.
17. K. Grundmann, K. Jaschonek, B. Kleine, J. Dichgans and H. Topka, Aspirin non-responder status in patients with recurrent cerebral ischemic attacks, J. Neurol. 250 (1) (2003), 63-66.